You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

5317 Results
Guidelines and Advice
Status: Archived
ID: 20-3
Jan 2016
Guidelines and Advice
Status: In-Review
ID: RR SCT-9
Version: N/A
Dec 1969
Regimen
Cancer Type:
Hematologic
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - In Combination with Rituximab for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iBRUtinib,
riTUXimab,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Guidelines and Advice
Status: Current
ID: PET 2024-1
Updated
Mar 2025
Guidelines and Advice
Status: In-Review
ID: GL-END 3-21
Jan 2018
Guidelines and Advice
Status: In-Review
ID: GL END 3-23
Version: N/A
Oct 2021
Guidelines and Advice
Status: In-Review
ID: GL END 3-24
Dec 1969
Guidelines and Advice
Status: Archived
ID: 15-15
Sep 2017
Guidelines and Advice
Status: In-Review
ID: 15-12
Version: 2
Jan 2015
Guidelines and Advice
Status: Current
ID: 17-4
Version: 2
Nov 2016
Document
Dec 1969
Document
Dec 1969

Pages